Dean Capital Investments Management LLC lowered its holdings in Chemed Co. (NYSE:CHE) by 7.3% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,389 shares of the company’s stock after selling 110 shares during the period. Dean Capital Investments Management LLC’s holdings in Chemed were worth $580,000 as of its most recent SEC filing.
Several other large investors have also made changes to their positions in the company. BlackRock Inc. grew its position in Chemed by 2.5% during the second quarter. BlackRock Inc. now owns 1,697,275 shares of the company’s stock valued at $612,445,000 after acquiring an additional 42,102 shares during the period. Investec Asset Management LTD boosted its position in shares of Chemed by 7.3% in the second quarter. Investec Asset Management LTD now owns 269,948 shares of the company’s stock worth $97,408,000 after buying an additional 18,449 shares during the period. Invesco Ltd. boosted its position in shares of Chemed by 7.4% in the second quarter. Invesco Ltd. now owns 262,075 shares of the company’s stock worth $94,567,000 after buying an additional 18,100 shares during the period. TimesSquare Capital Management LLC boosted its position in shares of Chemed by 27.9% in the second quarter. TimesSquare Capital Management LLC now owns 217,000 shares of the company’s stock worth $78,302,000 after buying an additional 47,300 shares during the period. Finally, Bank of New York Mellon Corp boosted its position in shares of Chemed by 4.5% in the second quarter. Bank of New York Mellon Corp now owns 201,475 shares of the company’s stock worth $72,700,000 after buying an additional 8,586 shares during the period. 88.69% of the stock is owned by institutional investors and hedge funds.
In other Chemed news, VP Naomi C. Dallob sold 2,300 shares of the company’s stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $413.00, for a total transaction of $949,900.00. Following the sale, the vice president now owns 8,486 shares in the company, valued at $3,504,718. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, VP Michael D. Witzeman sold 4,349 shares of the company’s stock in a transaction that occurred on Monday, August 19th. The shares were sold at an average price of $432.50, for a total value of $1,880,942.50. Following the sale, the vice president now owns 5,175 shares in the company, valued at approximately $2,238,187.50. The disclosure for this sale can be found here. In the last quarter, insiders sold 26,956 shares of company stock worth $11,446,181. Insiders own 3.96% of the company’s stock.
Several equities research analysts have recently weighed in on CHE shares. Bank of America upped their target price on Chemed from $470.00 to $500.00 and gave the stock a “buy” rating in a research report on Friday, September 6th. ValuEngine raised Chemed from a “sell” rating to a “hold” rating in a research report on Friday, November 1st. Oppenheimer upped their target price on Chemed from $400.00 to $430.00 and gave the stock an “outperform” rating in a research report on Thursday, August 1st. Royal Bank of Canada boosted their price target on Chemed to $405.00 and gave the stock a “sector perform” rating in a research note on Monday, July 29th. Finally, JMP Securities upgraded Chemed from a “market perform” rating to an “outperform” rating and set a $490.00 price target on the stock in a research note on Friday, November 1st. One analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $427.00.
Shares of NYSE:CHE traded up $2.37 during trading on Tuesday, hitting $408.20. The company’s stock had a trading volume of 18,267 shares, compared to its average volume of 81,991. The company has a debt-to-equity ratio of 0.32, a quick ratio of 0.64 and a current ratio of 0.67. Chemed Co. has a fifty-two week low of $260.03 and a fifty-two week high of $441.79. The stock’s 50-day moving average price is $412.44 and its two-hundred day moving average price is $385.03. The company has a market capitalization of $6.50 billion, a PE ratio of 34.22, a PEG ratio of 2.78 and a beta of 1.10.
Chemed (NYSE:CHE) last released its quarterly earnings results on Tuesday, October 29th. The company reported $3.46 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $3.31 by $0.15. Chemed had a return on equity of 35.06% and a net margin of 11.14%. The business had revenue of $480.61 million for the quarter, compared to analysts’ expectations of $478.89 million. During the same quarter in the previous year, the firm posted $3.07 earnings per share. The company’s revenue was up 8.2% compared to the same quarter last year. On average, equities analysts predict that Chemed Co. will post 13.47 earnings per share for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Monday, November 11th will be paid a $0.32 dividend. This represents a $1.28 annualized dividend and a dividend yield of 0.31%. The ex-dividend date of this dividend is Thursday, November 7th. Chemed’s dividend payout ratio (DPR) is 10.73%.
Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers in the United States. It operates through two segments, VITAS and Roto-Rooter. The company also offers plumbing, drain cleaning, water restoration, and other related services to residential and commercial customers through company-owned and independent contractors, and franchised locations.
Read More: What are earnings reports?
Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.